Humacyte, Inc.

Humacyte, Inc. is a commercial-stage biotechnology company developing bioengineered human tissues for implantation, with its first FDA-approved product, Symvess, now being launched in the United States. The company’s platform is designed to create off-the-shelf vascular grafts and other tissue constructs that can be manufactured at scale and used in trauma, vascular repair, and potentially hemodialysis access.

−5 044,6 %

−376,1 %

−2 003,6 %

3.69

2.95

— Humacyte, Inc.
%
Commercial product sales93% Sales of Symvess in the United States following FDA approval and commercial launch.
Contract revenue7% Revenue recognized under a customer contract to recover specified contract expenses.
Grant-supported development0% Government and other grants used to support R&D, scaling, and clinical trials.

Humacyte sells primarily to U.S. healthcare customers that use Symvess in vascular trauma care, with demand tied to...

  • U.S. trauma care providersprimary

    Hospitals and surgeons buying Symvess for vascular trauma cases because it is an FDA-approved off-the-shelf graft.

  • Potential hemodialysis access marketemerging

    Clinicians and health systems that may adopt ATEV products for AV access if regulatory approval is obtained.

  • Government and research funderssecondary

    Agencies and institutions providing grants or contract revenue to support development and clinical work.

  • Strategic and distribution partnerssecondary

    Partners such as Fresenius Medical Care that support commercialization, distribution, or future market access.

Humacyte’s commercial revenue is currently concentrated in the United States, where Symvess is being launched and sold...

  • •Commercial sales are currently generated in the United States
  • •FDA approval and U.S. launch drive near-term geographic exposure
  • •Grants and research support have come from U.S. institutions
  • •Future expansion depends on regulatory approvals in additional markets
  • •Reimbursement differences by country affect adoption speed

Humacyte’s near-term strategy is to build commercial traction for Symvess while preserving cash runway through cost...

01
Commercialize Symvess in the U.S.short-term

Product sales are the company’s first meaningful recurring revenue source and are central to proving market adoption.

02
Extend the ATEV platform into new indicationsmedium-term

Broader indications could expand the addressable market beyond trauma and improve long-term growth potential.

03
Scale manufacturing and supply chain capacitymedium-term

Commercial success depends on being able to produce off-the-shelf tissues reliably at scale.

04
Extend liquidity runway and secure financingshort-term

The company remains dependent on external capital until sales and cash flows become sufficient.

Humacyte remains a development-and-commercialization stage biotech with limited revenue history, so execution risk is...

high

Dependence on Symvess commercialization

The company’s future viability depends on generating cash flows from Symvess sales.

Scope
U.S. vascular trauma launch
Materiality
high
high

Financing and liquidity risk

The company expects to need additional capital beyond its current runway.

Scope
Equity, debt, collaborations, grants
Materiality
high
high

Manufacturing scale-up risk

Off-the-shelf bioengineered tissues must be produced consistently at commercial scale.

Scope
Facility expansion and supply commitments
Materiality
high
medium

Regulatory and reimbursement risk

Commercial success depends on payer coverage and future approvals for new indications.

Scope
CMS NTAP decision and future AV access approval
Materiality
high
medium

Cost reduction execution risk

Workforce cuts and expense reductions may not achieve expected savings and could cause impairment charges.

Scope
Operating model and organizational structure
Materiality
medium
Product revenue recognition
Reported revenue and gross margin
Contract revenue over time
Quarterly revenue timing and comparability
Fair value of derivative liabilities and contingent earnout
Net income volatility
Revenue interest liability
Interest expense and balance sheet leverage
Restructuring and impairment estimates
Operating expenses and asset values

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

uniQure N.V.

QURE · Pharmaceutical Preparations

Vaxcyte, Inc.

PCVX · Biological Products, (No Diagnostic Substances)

IOVANCE BIOTHERAPEUTICS, INC.

IOVA · Biological Products, (No Diagnostic Substances)

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

Zymeworks Inc.

ZYME · Pharmaceutical Preparations

: 28/04/2026